Nā huahana

ʻO Bromelain (BR) kahi protease cysteine ​​me nā hopena pale i ka huna ʻana o ka ʻōpū a me ka mumū.Eia naʻe, ʻaʻole i ʻike nui ʻia kona hopena i ka neʻe ʻana o ka ʻōpū.No laila, ua noiʻi mākou i ka hopena o kēia pūhui i loaʻa i ka mea kanu i ka contractility intestinal a me ka transit i nā ʻiole.Ua ana ʻia ka motility in vivo ma ka loiloi ʻana i ka puʻunaue ʻana o kahi māka fluorescent i hāʻawi waha ʻia ma ka ʻōpū liʻiliʻi.Ua loiloi pū ʻia ke kaʻa ma nā mokuʻāina pathophysiologic i hoʻokomo ʻia e ka ʻaila croton hui pro-inflammatory a i ʻole e ka diabetogenic agent streptozotocin. Ua kāohi ʻo Bromelain i nā contractions i hoʻoulu ʻia e nā pūhui spasmogenic like ʻole i loko o ka ileum ʻiole me ka mana like.Ua ho'ēmi a kū'ē paha ka hopena antispasmodic e ka proteolytic enzyme inhibitor, gabexate (15 × 10 (-6) mol L (-1) ), protease-activated r eceptor-2 (PAR-2) antagonist, N (1) -3 -methylbutyryl-N(4) -6-aminohexanoyl-piperazine (10(-4) mol L(-1) ), phospholipase C (PLC) inhibitor, neomycin (3 × 10(-3) mol L(-1) ) , a me ka phosphodiesterase 4 (PDE4), rolipram (10(-6) mol L(-1) ).In vivo, BR preferentially inhibited motility i pathophysiologic states in a PAR-2-antagonist-sensitive manner.Our ikepili hōʻike i ka BR inhibits intestinal motility - preferentially in pathophysiologic conditions - me kahi mīkini e pili ana i ka membrane PAR-2 ​​a me PLC a me PDE4 ma ke ano intracellular. nā hōʻailona.Hiki i ka Bromelain ke lilo i mea alakaʻi no ka hoʻomohala ʻana i nā lāʻau hou, hiki ke hoʻomaʻamaʻa i ka neʻe ʻana o ka ʻōpū i ka mumū a me ka maʻi diabetes.